Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jan 8, 2013

Top 25 M&A Deals of 2012

Who bought who last year? Find out here.

Top 25 M&A Deals of 2012

Big bucks were spent on M&As last year. Read on to find out which deal was worth the most. [© Ben Chams - Fotolia.com]

  • #12. Ardea

    Acquired by: AstraZeneca

    Price: $1.26 billion

    Deal Completed: June 19

    Premium: 54%

  • #11. Fougera

    Acquired by: Novartis

    Price: $1.525 billion

    Deal Completed: July 23

    Premium: N/A

  • #10. Par Pharmaceuticals

    Acquired by: TPG Capital

    Price: $1.9 billion

    Deal Completed: Sept. 28

    Premium: 37%

  • #9. Dako

    Acquired by: Agilent Technologies

    Price: $2.2 billion

    Deal Completed: June 21

    Premium: N/A

  • #8. Inhibitex

    Acquired by: Bristol-Myers Squibb

    Price: $2.5 billion

    Deal Completed: Feb. 13

    Premium: 163%

  • #7. Medicis

    Acquired by: Valeant Pharmaceuticals

    Price: $2.6 billion

    Deal Completed: Dec. 11

    Premium: 39%

  • #6. Boston Biomedical

    Acquired by: Dainippon Sumitomo Pharma

    Price: $2.63 billion9

    Deal Completed: April 24

    Premium: N/A

  • #5. Human Genome Sciences

    Acquired by: GlaxoSmithKline

    Price: $3 billion

    Deal Completed: Aug. 3

    Premium: 99%

  • #4. Gen-Probe

    Acquired by: Hologic

    Price: $3.8 billion

    Deal Completed: Aug. 1

    Premium: 20%

  • #3. Amylin Pharmaceuticals

    Acquired by: Bristol-Myers Squibb

    Price: $5.3 billion10

    Deal Completed: Aug. 8

    Premium: 101%

  • #2. Actavis Group

    Acquired by: Watson Pharmaceuticals11

    Price: $5.547 billion11

    Deal Completed: Oct. 31

    Premium: N/A

  • #1. Pharmasset

    Acquired by: Gilead Sciences

    Price: $11.2 billion

    Deal Completed: Jan. 17

    Premium: 90%



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »